Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Summit Therapeutics Inc.

NASDAQ: SMMT · Life Sciences · 7 alerts · CIK 1599298

Share price
$11.82Close, Nov 16
Market cap
$9.45B
Shares outstanding
799.76MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Summit Therapeutics Inc. filings on SEC EDGAR ↗

6:14 AM ET 8-K
Other 8-K Filing

Summit Therapeutics Other 8-K Filing

Summit Therapeutics received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for ivonescimab in combination with chemotherapy for certain lung cancer patients. The FDA determined that the BLA cannot be approved in its current form because the progression-free survival benefit did not establish substantial evidence of effectiveness without a statistically significant improvement in overall survival.

Counterparty
FDA
5:23 PM ET 8-K
Capital Raise

Summit Therapeutics Capital Raise

Summit Therapeutics Inc. filed a prospectus supplement to its automatic shelf registration statement on Form S-3 for the potential issuance of common stock. The filing includes a legal opinion from Baker & Hostetler LLP regarding the legality of the shares being offered.

5:08 PM ET 10-Q
Financial Results

Summit Therapeutics Q3 2026 Results: Net Loss of $208M, Loss Narrows

Summit Therapeutics reported a net loss of $613.5 million for the nine months ended September 30, 2026, compared to a net loss of $860.4 million in the prior year period. The company ended the quarter with $629.8 million in cash, cash equivalents, and short-term investments, while total stockholders' equity decreased to $564.7 million from $658.9 million at year-end 2025.

Key figure
Net loss $208M
4:52 PM ET 8-K
Financial Results

Summit Therapeutics Financial Results

Summit Therapeutics reported its Q3 2026 financial results, highlighting a $2.0 billion strategic equity investment from AstraZeneca received post-quarter. The company ended the period with $629.8 million in cash and is advancing its global clinical development program for ivonescimab across multiple solid tumor indications.

“This quarter marked a period of meaningful momentum for Summit, highlighted by AstraZeneca’s $2 billion strategic equity investment and the expansion of our network of clinical collaborations with AstraZeneca, Daiichi Sankyo, and several others.”

Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit

“Our global clinical development program for ivonescimab continues to broaden, with the announcement of ivonescimab combination collaborations with Datroway® and sone-ve, alongside new studies in bladder cancer with HARMONi-GU1, in biliary tract cancer with EA2251, and in kidney cancer with SMT112-216 and Arcus’ ARC- 20 platform study.”

Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.